December 23, 2024 – OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADC) and active immunotherapies (4174.

浩鼎ADC新藥OBI-992論文 榮登國際期刊Molecular Cancer Therapeutics (MCT)封面 推薦為首度揭露精選文章. 台灣浩鼎生技 (4174.TWO) 旗下自行研發的以TROP2為標靶的抗體藥物複合體 (Antibody-Dr […]

OBI Pharma, Inc. is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States (OBI Pharma USA, Inc.) and Australia (OBI Pharma Australia Pty Ltd). It was founded in 2002 by Dr. Michael Chang, an accomplished biotech entrepreneur in the United States.

OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan. [1] [2] In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular ...

NEWARK, U.S.A. and NANJING, China, June 14, 2024 — OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor types.

2024年8月8日 · obi-992为博奥信与obi共同开发，是一种靶向trop2的adc药物分子，今年6月在美国启动临床i/ii期试验，招募晚期实体瘤患者包括胃癌（gc）和其他潜在癌症患者，以验证obi-992的安全性、药代动力学和初步疗效。

2022年2月22日 · The company's novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin (formerly OBI-822) and OBI 833, a Globo H active immunotherapy vaccine; OBI-888...

TAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate...

The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADCs) drugs for patients, in addition to its promising Globo H active immunotherapy. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets.

2024年1月3日 · OBI Pharma Inc. First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody - drug conjugate (ADC) targeting TROP2.